Pāriet uz galveno navigāciju Pāriet uz meklēšanu Pāriet uz galveno saturu

Evaluation of systemic targeting of RET oncogene-based MTC with tumor-selective peptide-tagged Ad vectors in clinical mouse models

  • A. Schmidt
  • , C. Eipel
  • , K. Fürst
  • , N. Sommer
  • , J. Pahnke
  • , B. M. Pützer
  • University of Rostock

Zinātniskās darbības rezultāts: Devums žurnālam › Zinātniskais raksts (žurnālā) › koleģiāli recenzēts

8 Atsauces (Scopus)

Kopsavilkums

Significant advantage of targeted antitumoral treatment consists in the possibility to restrict maximum therapeutic efficacy to the malignant cell population by reducing toxicity in healthy tissues. Using different clinical models for aggressive medullary thyroid carcinoma (MTC), we have recently identified peptide ligands that bind highly selective to tumor cells. By linking the most convincing SRESPHP peptide to an adenoviral (Ad) vector expressing the MTC-related oncogene inhibitor RETΔTK, gene transfer was specifically directed to neoplastic tissue after systemic virus administration. We show that peptide-mediated delivery of RETΔTK significantly enhanced apoptosis, resulting in a strong inhibition of orthotopic and xenograft tumor growth. Conversely, tumors treated with controls expanded their initial size without notable cell death. According to the therapeutic effect, strong virus accumulation was found exclusively in thyroid carcinomas. Strikingly, application of native tropism depleted viral vector linked to tumor-selective peptide was accompanied by a substantial reduction of Ad binding to the liver. Of note, single systemic injection of a low dose (10e8 pfu/mouse) of MTC-specific Ad.RETΔTK induced regression of multiple tumors at different sites in all treated animals. In sum, our results open up the possibility for an efficient cancer cell-specific therapy of primary MTC, their migrating populations and potentially metastases.

OriģinālvalodaAngļu
Lapas (no-līdz)418-423
Lapu skaits6
ŽurnālsGene Therapy
Sējums18
Izdevuma numurs4
DOIs
Publikācijas statussPublicēts - apr. 2011
Ārēji publicētsJā

ANO IAM

Šis izpildes rezultāts palīdz sasniegt šādus ANO ilgtspējīgas attīstības mērķus (IAM)

  1. 3. IAM — Laba Veselība un Labbūtība
    3. IAM — Laba Veselība un Labbūtība

Nospiedums

Uzziniet vairāk par pētniecības tēmām “Evaluation of systemic targeting of RET oncogene-based MTC with tumor-selective peptide-tagged Ad vectors in clinical mouse models”. Kopā tie veido unikālu nospiedumu.

Citēt šo